stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Shares outstanding
HUTCHMED (China) Limited Sponsored ADR's shares outstanding at the end of fiscal 2025 was $174.6M, unchanged from fiscal 2024. Over the past ten years it has ranged from $109.3M (fiscal 2015) to $174.6M (fiscal 2025) — the current reading is the highest in ten years. HUTCHMED (China) Limited Sponsored ADR ranks 16th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $174.6M | 0.01% |
| FY2024 | $174.6M | 0.42% |
| FY2023 | $173.8M | 2.60% |
| FY2022 | $169.4M | 6.87% |
| FY2021 | $158.5M | 13.58% |
| FY2020 | $139.6M | 4.84% |
| FY2019 | $133.1M | 0.21% |
| FY2018 | $132.9M | 7.63% |
| FY2017 | $123.4M | 3.35% |
| FY2016 | $119.4M | 9.25% |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ALVO Alvotech compare | $295.0M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $267.6M |
| HCM HUTCHMED (China) Limited Sponsored ADR | $214.3M |
| TRLV Trulieve Cannabis Corp. compare | $200.6M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.9M |
| PRGO Perrigo Company plc compare | $139.4M |
| PBH Prestige Consumer Healthcare Inc. compare | $47.6M |
| ANIP ANI Pharmaceuticals, Inc. compare | $21.7M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement